ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1895

Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis

Jessica Murillo Saich1, Roxana Coras2, Robert Meyer3, Nancy Lane4 and Monica Guma5, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, San Diego, CA, 3San Diego VA Healthcare Service, San Diego, CA, 4University of California Davis, Hillsborough, CA, 5UCSD, La Jolla, CA

Meeting: ACR Convergence 2022

Keywords: metabolomics, Osteoarthritis, pain, WOMAC

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated by low-grade synovial inflammation (synovitis) that contributes to joint pain and stiffness, especially in knee OA (KOA). In addition, chronic inflammatory responses are associated with dramatic shifts in tissue metabolism. The objective of this work is to explore the metabolomic profiling in synovial tissue (ST) from OA patients and its association with pain.

Methods: Synovial tissue (ST) and synovial fluid (SF) samples were collected from patients with OA during knee replacement. ST was snap-frozen for metabolomic analysis. The patients were interrogated about nociceptive and neuropathic pain using WOMAC and the painDETECT questionnaires respectively. Nerve Growth Factor (NGF) was quantified in SF by enzyme-linked immunosorbent assay (ELISA). A 600 MHz Bruker Avance III spectrometer 1H-NMR was used to acquire NMR spectra of ST samples. Software Chenomx NMR suite 8.5 professional was used for metabolite identification and quantification. The samples were normalized by volume/weight and the concentrations were reported in μM. Metaboanalyst 5.0, SPSS v26, and R studio were used for statistical analysis.

Results: 23 male patients (average age: 68 years, standard deviation (SD) 6.59, average BMI 28.2, SD 3.9) were recruited. At the time of the surgery, patients had a mean total WOMAC of 54.5 (SD, 18.2), WOMAC pain of 11.63 (SD 13.55), WOMAC stiffness of 4.7 (SD 1.6), WOMAC difficulty of 37.9 (SD 13.5), and painDETECT of 14.9 (SD 7.5). NGF levels in SF had a mean of 34 (SD 14.5) ng/mL. 47.8% of patients were classified as low pain (WOMAC pain ≤10) and 52.2% as high pain (WOMAC pain >10). For neuropathic pain, 37.5% were classified as unlikely (PainDETECT ≤12), and 62.5% likely (PainDETECT >12). NGF from SF was positive correlated with painDETECT (r=0.60, p=0.030) but not with WOMAC pain (r=0.21, p=0.35). Several metabolites, including creatine phosphate, glycine and tyrosine had a positive correlation with painDETECT, and acetoacetate had a negative correlation. Dimethylamine, proline, tryptophan and valine correlated positively and threonine negatively with WOMAC pain. The orthogonal partial least square discriminant analysis (OPLS/DA) showed a good separation of patients for painDETECT and WOMAC pain Phenylalanine and tyrosine metabolism, and phenylalanine, tyrosine and tryptophan biosynthesis were enriched metabolic pathways in patients with likely neuropathic pain (Figure 1), while pirimidine and tryptophan metabolism contributed to the discrimination between low and high WOMAC pain (Figure 2).

Conclusion: Neuropathic and nociceptive pain showed a different association with metabolomic profiling in tissue with OA. NGF in SF was associated only to neuropathic pain. Several metabolites differentially correlated with WOMAC and painDETECT suggesting different metabolic pathways involved in knee OA pain. Further studies are needed to determine whether metabolomic profiling of synovial tissue can identify new therapeutic targets for pain of OA.

Supporting image 1

Figure 1. Metabolomic profiling discriminates patients with likely and unlikely neuropathic pain. A) OPLS-DA according to painDETECT classification showed a clear separation between groups with good predictive performance (Q2=0.102); B) Phenylalanine, tyrosine and serine were the 3 metabolites with higher VIP score; C) Enrichment pathways showed that phenylalanine and tyrosine metabolism are higher in patients with likely neurpatic pain according to painDETECT.

Supporting image 2

Figure 2. Metabolomic profiling discriminates patients with high and low nocioceptive pain. A) OPLS-DA between low pain versus high WOMAC pain shows a clear separation between groups with good predictive performance (Q2=0.256); B) Uridine, tryptophan and trimethylamine were the metabolites with higher VIP score; C) Enrichment pathways showed that pirimidine and tryptophan metabolism contribute to the discrimination between low and high WOMAC pain


Disclosures: J. Murillo Saich, None; R. Coras, None; R. Meyer, None; N. Lane, Amgen, GlaxoSmithKlein(GSK); M. Guma, Pfizer, Novartis, Gilead, Sonoma Bio, Genentech.

To cite this abstract in AMA style:

Murillo Saich J, Coras R, Meyer R, Lane N, Guma M. Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-between-synovial-tissue-metabolomic-profile-and-pain-in-patients-with-knee-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-synovial-tissue-metabolomic-profile-and-pain-in-patients-with-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology